Trial Profile
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA): A Randomized Placebo-controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- Acronyms OKINADA
- 14 Nov 2022 Results assessing the efficacy and safety of a TNF alpha inhibitor, adalimumab, in a proof-of-concept study in patients with inflammatory OA of the knee, presented at the ACR Convergence 2022.
- 04 Jun 2022 Primary endpoint has not been met. (Primary Endpoint: the percentage of subjects achieving an OARSI/OMERACT response at Week 16)
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism